Afschin Gandjour, MD, PhD
Potential Financial Conflicts of Interest: None disclosed.
Gandjour A. Survivor Costs in Cost-Effectiveness Analysis. Ann Intern Med. 2006;144:534-535. doi: 10.7326/0003-4819-144-7-200604040-00020
Download citation file:
Published: Ann Intern Med. 2006;144(7):534-535.
TO THE EDITOR:
Golan and colleagues (1) present a cost-effectiveness analysis of several anti-Candida strategies for high-risk patients in the intensive care unit. They evaluate treatment effectiveness by the number of life-years that are gained from reduced hospital mortality rates. The authors included initial hospitalization costs in their calculations. This approach, however, overestimates treatment cost-effectiveness and provides unduly favorable cost-effectiveness ratios. When treatment effectiveness is assessed by the number of life-years gained, costs for health care services that are required to provide this gain must also be included (2). After all, the anti-Candida therapy and the initial hospital stay are responsible not only for the life-years gained but also for health care services that are delivered in the years between hospital discharge and death. Therefore, the appropriate approach is to include all health care costs (or at least those responsible for life extension) that are incurred during the period between hospital discharge and death.
Learn more about subscription options.
Register Now for a free account.
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only